Bioequivalence of a hybrid pegylated liposomal doxorubicin hydrochloride injection and Caelyx®: A single-dose, randomized, multicenter, open-label, two-period crossover study in patients with advanced ovarian cancer-Reference-Cited by-同舟云学术

Bioequivalence of a hybrid pegylated liposomal doxorubicin hydrochloride injection and Caelyx®: A single-dose, randomized, multicenter, open-label, two-period crossover study in patients with advanced ovarian cancer

Published:2022-09 Issue: Volume:176 Page:106248
ISSN:0928-0987
Container-title:European Journal of Pharmaceutical Sciences
language:en
Short-container-title:European Journal of Pharmaceutical Sciences

Author:

S． Prakash S.,Nagarkar Rajnish Vasant,Puligundla Krishna Chaitanya,N． Lokesh K.,Boya Rakesh Reddy,Patel Ankit Baldevbhai,Goyal Lovenish,Thoke Aniket,Patel Jigar Gordhanbhai,Mehta Ajay Omprakash,Patel Ghanshyam Nanubhai,Khan Mujtaba A.,Ahmad Imran

Funder

Intas Pharmaceuticals

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference19 articles.

1. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials;Alberts;Semin. Oncol.,2004

2. Bioequivalence study of pegylated doxorubicin hydrochloride liposome (PEGADRIA) and DOXIL® in ovarian cancer patients: physicochemical characterization and pre-clinical studies;Ali;J. Nanomed. Nanotechnol.,2016

3. Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil® or Caelyx® in advanced ovarian cancer;Bhowmik;Cancer Chemother. Pharmacol.,2018

4. Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion,2006

5. The role of oxygen-derived free radicals in the cytotoxicity of doxorubicin in multidrug resistant and sensitive human ovarian cancer cells;Cervantes;Cancer Lett.,1988

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding the In Vitro-In Vivo Nexus: Advanced correlation models predict clinical performance of liposomal doxorubicin;International Journal of Pharmaceutics;2024-04

2. Nanoparticles in Medicine: Current Status in Cancer Treatment;International Journal of Molecular Sciences;2023-08-15

3. Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity;Cells;2023-02-19

4. Cancer nanomedicine: a review of nano-therapeutics and challenges ahead;RSC Advances;2023

5. A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx ® in advanced breast cancer;Frontiers in Oncology;2022-12-20